2025 VBEF Future Healthcare & Pharma Top 100 Expo: Where 1,000+ Capital Buyers Meet 2,000+ Innovative Assets
In 2025, as the “Healthy China 2030” initiative enters its final five-year sprint, two trends have become evident: listed companies are leading the performance recovery, while investment and financing activities in the primary market have significantly increased; a large number of high-quality innovative assets and projects in the healthcare and pharmaceutical sectors are going global, accelerating their integration into the global value ecosystem. Looking beyond these phenomena to their essence—amidst global shifts driven by aging populations and the restructuring of geopolitical landscapes—high-quality innovative healthcare and pharmaceutical assets that combine efficiency with innovation are becoming essential choices for international capital allocation.
This May, an industry roundtable focused on high-quality assets in China’s medical and pharmaceutical innovation is set to take place.May 9–10, the 2025 VBEF Future Healthcare & Pharmaceuticals Top 100 Exhibition (VBEF) will be held at the Suzhou International Expo CenterBy adopting the integrated “forum + exhibition + transaction” model, it forges deep connections between high-quality assets and global capital, local industrial chains, and end-user medical institutions, thereby facilitating the leap from “innovation capability” to “productivity” for China’s premium healthcare and pharmaceutical innovation assets.
Among them,, a two-day main forum, will centrally present the latest insights from participants in China's healthcare and pharmaceutical industry,Academicians of the Chinese Academy of Sciences, discipline leaders, executives of multinational corporations, industry-leading companies, and high-growth enterprises, as well as frontline investors and other prominent figures in the field, we will stand at the “tipping point” of development in the healthcare and pharmaceutical industries, interpret shifts in macroeconomic trends, identify directions for industrial innovation, learn from exemplary corporate solutions, and explore global strategic layout.
High-Density Dialogue Among Leaders from Government, Industry, Academia, Research, Healthcare, and Investment: Anchoring the Development Trends of China’s High-Quality Assets
How high are the caliber of guests and the information density at the VBEF Main Forum? Both the macro and micro aspects of China’s healthcare and pharmaceutical industries are integrated into this conference.
On the 9th, the main forum examined global trends and industrial innovation from a macro perspective.
Gao Guobiao, former Party Secretary and Deputy Director of the Center for Medical Device Evaluation under the former China Food and Drug Administration, and Li Datao, Founder of VCBeat, will deliver opening remarks at the conference. The Bill & Melinda Gates Foundation and Qingsong Health Group will share insights on how advanced technologies, such as AI, are empowering global health from a technical perspective.
On the production and investment sideRepresented by Aier Eye Hospital, Gushengtang, and United LiGe, the private healthcare sector; high-tech forces represented by United Imaging Intelligence, DAMO Academy’s Medical AI Lab, and MicroPort MedBot; and the investment perspective represented by Sherpa Capital will together ignite a thought-provoking storm around premium assets in the healthcare and pharmaceutical industries. Meanwhile, Fangzhou Securities, Jinpu Health Services, and Yaoyi Cloud Technology will examine emerging industry trends from the perspectives of industrial research and regulatory compliance.
In the academic and research sectorDistinguished guests, including an Academician of the Chinese Academy of Sciences, the former Director of the Department of System Reform under the National Health Commission, and the Director of the Center for Aging Development Strategy Research at Nankai University, were in attendance to share their insights on global trends in the healthcare and pharmaceutical industries from the perspectives of technological innovation and healthcare systems.
Specially Added “Academic Center Migration” Section, inviting the founding editor-in-chief of Science Robotics, the editorial director of Chinese Science Bulletin & Science Bulletin, and the founder of The Innovation academic journal to discuss China’s opportunities amid the global shift of academic centers.
On the 10th, focusing on individual development, we will gather high-quality assets and buyers to achieve value fission for China's innovative medical and pharmaceutical assets.
JLL’s Life Sciences Real Estate division brings together cross-industry expertise. Premium buyers—including state-owned investment firms, venture capital (VC) firms, corporate venture capital (CVC) arms, and industrial investors—such as Legend Star, Junlian Capital, Medtronic China Fund, Yuanhe Origin, Wuxi Innovation Investment Group, Huagai Medical Investment, and Pivotal bioVenture, will disclose their investment methodologies. Meanwhile, high-quality assets represented by JD Health, iFlytek Healthcare, Knowledge Matrix, Shanwaishan, Tupai Medical, Yuwell Medical, and Kangqiao Medical will share their corporate development strategies.
Globalization is also a key theme of this forum, led by Zhang Yuhui, a member of the Party Committee of the Hainan Provincial Health Commission, the International Cooperation Department of the China Medical Equipment Association and the International Department of the China United Nations Procurement Promotion Association discussed practical pathways for the internationalization of Chinese assets; Northeast Securities, Guotai Haitong Securities Investment, Hornet Capital, and AllBright Law Offices focused their discussions on cross-border business development (BD) practices in the medical device sector.
Overall,Main Forum: Trending Tipping Points, Optimal Solutions Below the Tipping Point, and Development Opportunities Beneath the Tipping PointThree Major Sectors: Guests from the Six Circles of Government, Industry, Academia, Research, Healthcare, and Investment Observe Macro Trends and Focus on Micro Practices to Discuss Growth Engines for China’s Healthcare Industry and Precisely Identify High-Quality Asset Growth Points.
Concurrent N+ Activities: High-Quality Assets + Premium Buyers, Building a Global Trading Network for Chinese Assets
To facilitate precise resource alignment, VCBeat is concurrently hosting a series of N+ activities during the VBEF, including closed-door government-enterprise meetings, premium asset promotion sessions, and innovative product launches. By adopting an integrated “exhibition + forum + transaction” model, VCBeat fosters deep connections between high-quality assets and global capital, local industrial chains, and end-user medical institutions, thereby empowering China’s innovative healthcare and pharmaceutical assets to bridge the gap from “innovation capability” to “productive capacity.”
The Exhibition Achieves Diversified Matchmaking:2025 VBEF Special Exhibition Area DesignCentral Stage (Thematic Roadshows, Product Launches), Innovative Product Showcase (Product Demonstrations, Case Studies)、Innovative Assets Poster Exhibition (TOP 100 Investment Landscape, Resource Matching)Three Major Value Domains: Accelerating the Value Fission of High-Quality Innovative Assets in China’s Healthcare and Pharmaceutical Industries Through Innovative Models and Efficient Mechanisms.
Forum Decoding Trends:2 Main Forums, 4 Featured Forums, and 20+ Thematic Forums comprehensively cover the hot sectors of high-quality innovative assets in China’s healthcare and pharmaceutical industries. Over 300 industry leaders, academicians, experts, and corporate executives will discuss the growth poles of China’s healthcare industry, precisely identifying growth drivers for high-quality assets.
High-Efficiency Transaction Scenarios:Exhibiting companies can engage directly with international buyers, overseas distributors, and supply chain partners. Through on-site negotiations and demand-matching sessions, they can swiftly secure business opportunities in cross-border cooperation, technology introduction, and product distribution, thereby facilitating the integration of China’s high-quality innovative medical and pharmaceutical assets into the global industrial chain.
Welcome to all industry partners to register, engage in direct communication and negotiate collaborations with innovative enterprises.
Tipping Point, Seizing the Initiative
Exhibition Name:2025 VBEF Future Healthcare & Pharma Top 100 Expo
Exhibition Dates:May 9–10, 2025
Venue:China · Suzhou · International Expo Center
Exhibition Scale:16,000+ visits
